NEUROPATHOLOGY CORE 1. MAIN OBJECTIVES AND NEW DIRECTIONS The Experimental Neuropathology Laboratory (ENL) at the Neurosciences and Pathology Departments at UCSD is primarily focused at better understanding the mechanisms of synaptic pathology and at developing new experimental therapies for Alzheimer's Disease (AD), Parkinson's Disease (PD), HIV associated dementia (HAD), and other neurodegenerative conditions. This laboratory is headed by Dr. Eliezer Masliah, who has collaborated with a number of neuroscientists on the La Jolla Torrey Pines Mesa and elsewhere, but these facilities have not been previously available to all neuroscientists as a Core. Dr. Masliah will serve as Director of the proposed New Neuropathology Core, which will be located at UCSD. We propose, via this grant proposal and in the spirit of the NIH Blueprint mission, to make this facility into a Core and to therefore make it readily available to other neuroscientists in the region. This new Core will foster further collaborations and enhance research into neurodegenerative disorders in the San Diego area. In recent years, with establishment of more sophisticated animal models of neurological disorders and the considerable growth of the neurosciences groups interested in neurodegenerative diseases at UCSD, the Burnham Institute for Medical Research (BIMR), The Scripps Research Institute (TSRI), and The Salk Institute, an increased demand for core services focused at characterizing neuropathological alterations in human and animal models has developed. Furthermore, interest has grown not only from the fields of AD, PD and HAD, but also in stroke, trinucleotide repeat disorders (such as Huntington's disease), taupathies, prion diseases, amyotrophic lateral sclerosis (ALS), and multiple sclerosis, just to mention a few. This has created a considerable need for the formation of a consolidated and unified Core Neuropathology Facility that will provide support and help coordinate efforts to all of these different programs. In this context, the overall objective of the Neuropathology Core is to provide to investigators in the La Jolla Neurosciences community a set of technical and neurobiological resources that allows analysis of the degenerative processes associated with neurological conditions in human brains and animal models from a comprehensive and dynamic perspective. The Core will allow the acquisition and analysis of Neuropathology related data with standardized protocols. CORE RESOURCE OBJECTIVES 1) Provide an array of techniques including histopathology, immunocytochemistry, microinjection, confocal microscopy, stereology, electron microscopy, digital imaging and 3D reconstruction to facilitate quantitative analysis of neuronal injury that will facilitate studies of the pathogenesis of degenerative, inflammatory and demyelinating CNS disorders. 2) Provide technical assistance on state-of-the-art neuropathological approaches such as twophoton confocal microscopy and immuno-electron microscopy. 3) Provide scientific consultation on molecular pathogenesis and targets of neurological disorders. 4) Support preliminary studies in human tissues and animal models that utilize neuropathology data. 5) Provide mentorship for students and junior faculty in the theory and techniques of neurobiology and neuropathology. 6) Collaborate with the other Cores of the program to disseminate information on neuropathology related methods of analysis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Center Core Grants (P30)
Project #
5P30NS057096-04
Application #
7925711
Study Section
Special Emphasis Panel (ZNS1)
Project Start
2009-09-01
Project End
2011-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
4
Fiscal Year
2009
Total Cost
$295,187
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Singec, Ilyas; Crain, Andrew M; Hou, Junjie et al. (2016) Quantitative Analysis of Human Pluripotency and Neural Specification by In-Depth (Phospho)Proteomic Profiling. Stem Cell Reports 7:527-542
Kim, Changyoun; Lv, Guohua; Lee, Jun Sung et al. (2016) Exposure to bacterial endotoxin generates a distinct strain of ?-synuclein fibril. Sci Rep 6:30891
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34
Kratter, Ian H; Zahed, Hengameh; Lau, Alice et al. (2016) Serine 421 regulates mutant huntingtin toxicity and clearance in mice. J Clin Invest 126:3585-97
Kim, Changyoun; Lee, He-Jin; Masliah, Eliezer et al. (2016) Non-cell-autonomous Neurotoxicity of ?-synuclein Through Microglial Toll-like Receptor 2. Exp Neurobiol 25:113-9
Mandler, Markus; Valera, Elvira; Rockenstein, Edward et al. (2015) Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 10:10
Tang, Bin; Wang, Tingting; Wan, Huida et al. (2015) Fmr1 deficiency promotes age-dependent alterations in the cortical synaptic proteome. Proc Natl Acad Sci U S A 112:E4697-706
Rockenstein, Edward; Overk, Cassia R; Ubhi, Kiren et al. (2015) A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies. PLoS One 10:e0121570
Hoefer, Melanie M; Sanchez, Ana B; Maung, Ricky et al. (2015) Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system. Exp Neurol 263:221-34
Valera, Elvira; Mante, Michael; Anderson, Scott et al. (2015) Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J Neuroinflammation 12:93

Showing the most recent 10 out of 105 publications